SCHEMBL6490625

SCHEMBL6490625

COc1ccccc1-c1cnc(C(=O)NC2CC3CC2CN3)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
CHRNA7 P36544 2/20 0.44
DGAT1 O75907 1/20 0.40
USP30 Q70CQ3 1/20 0.39
CTSA P10619 3/20 0.38
CHEK1 O14757 1/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 2/20 0.37
STK17B O94768 1/20 0.37
PDE7A Q13946 1/20 0.36
PDE10A Q9Y233 1/20 0.36
HTR3A P46098 1/20 0.36
APP P05067 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CSNK2A2 P19784 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498058 0.87 USP30 (0.40) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6488002 0.85 USP30 (0.39) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6490674 0.85 HDAC1 (0.48) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6494676 0.85 USP30 (0.38) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6486475 0.85 USP30 (0.38) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6497526 0.84 HDAC6 (0.48) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6500511 0.84 CHRNA7 (0.63) HDAC6CHRNA7HTR3AAPPALDH1A1
SCHEMBL7234242 0.83 HDAC3 (0.47) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6498771 0.83 USP30 (0.38) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6496553 0.83 HDAC1 (0.48) HDAC1HDAC6DGAT1USP30NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 HDAC3 1855/4885HDAC1 467/4885HDAC2 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.